A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men - Trial NCT06337110
Access comprehensive clinical trial information for NCT06337110 through Pure Global AI's free database. This Phase 1 trial is sponsored by H. Lundbeck A/S and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
H. Lundbeck A/S
Timeline & Enrollment
Phase 1
Apr 10, 2024
May 25, 2024
Primary Outcome
Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces),AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity,Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material,Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material,T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material,AUC0-infinity of Lu AF28996,Cmax of Lu AF28996,Tmax of Lu AF28996,T½ of Lu AF28996
Summary
The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of
 the body after a single dose is given to healthy male participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06337110
Non-Device Trial